A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~16 mi. (Bebington, United Kingdom, +172 more cities)

The Clatterbridge Cancer Centre

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

~16 mi. (Bebington, United Kingdom, +104 more cities)

The Clatterbridge Cancer Centre NHS Foundation Trust

FGFR2 Fusion

Cholangiocarcinoma

infigratinib

targeted therapy

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~16 mi. (Bebington, United Kingdom, +144 more cities)

Clatterbridge Centre For Oncology

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

~16 mi. (Bebington, United Kingdom, +29 more cities)

The Clatterbridge Cancer Centre NHS Foundation Trust

Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers

Cutaneous Melanoma, +4 more conditions

nivolumab, +1 more drug

immunotherapy

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

~16 mi. (Bebington, United Kingdom, +11 more cities)

Clatterbridge Centre for Oncology

Malignant Solid Tumor

BAY2416964, +1 more drug

immunotherapy

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

~16 mi. (Bebington, United Kingdom, +7 more cities)

The Clatterbridge Cancer Centre NHS Foundation Trust

FOLH1 Expression

Malignant Solid Tumor

CB307

targeted therapy

Study of RP3 Monotherapy and RP3 in Combination With Anti-PD1 Therapy in Patients With Solid Tumours

~16 mi. (Bebington, United Kingdom, +3 more cities)

The Clatterbridge Cancer Centre NHS Foundation Trust

Malignant Solid Tumor

anti-PD-1 antibody, +1 more drug

immunotherapy

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

~16 mi. (Bebington, United Kingdom, +3 more cities)

The Clatterbridge Cancer Centre NHS Foundation Trust

Malignant Solid Tumor

nivolumab, +1 more drug

immunotherapy

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~19 mi. (Birkenhead, United Kingdom, +199 more cities)

The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0757)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

~19 mi. (Liverpool, United Kingdom, +145 more cities)

Clatterbridge Cancer Center NHS FT ( Site 1800)

Non-Small Cell Lung Carcinoma

pembrolizumab, +1 more drug

immunotherapy, +2 more types

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~21 mi. (Wirral, United Kingdom, +356 more cities)

Clatterbridge Cancer Centre

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

~38 mi. (Rhyl, United Kingdom, +92 more cities)

Betsi Cadwaladr University Health Board ( Site 0447)

Bladder Urothelial Carcinoma

chemotherapy, +2 more drugs

chemotherapy, +2 more types